VUSE Vident U.S. Equity Strategy ETF
Profitability Metrics
Valuation Metrics
Growth & Cash Flow
Price Change
Top 10 Holdings
| Stock Ticker | Weight |
|---|---|
| ABBV | 2.52% |
| AVGO | 2.52% |
| GOOGL | 2.44% |
| NVDA | 2.39% |
| LLY | 2.33% |
| MA | 2.13% |
| ORCL | 2.13% |
| AMZN | 2.12% |
| COST | 2.11% |
| JNJ | 2.10% |
ETF Analysis
Fund Overview
Vident U.S. Equity Strategy ETF (VUSE) currently reports 125 stock positions (subject to change), placing it in the broadly constructed range by holdings breadth. The top line-up is ABBV (2.52%), AVGO (2.52%), GOOGL (2.44%), with ABBV as the largest single weight at 2.52%. Together, the top three holdings account for 7.48%, which suggests the fund is not overly reliant on its largest positions to generate returns. The fund's architecture positions it to benefit from strength in its top holdings while the broader basket provides a degree of insulation against single-name shocks.
Profitability & Capital Efficiency
Looking at how effectively the underlying holdings deploy capital, ROIC is 41.25%, WACC is 10.13%, and the economic spread is 31.12%. On balance, holdings are earning returns on capital well in excess of what investors and creditors require — the defining characteristic of a high-quality compounding portfolio. Supporting metrics show ROE at 53.77% and ROA at 14.85%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a portfolio with credible compounding capacity if current operating execution persists.
Valuation
On an earnings multiple basis, trailing P/E of 26.05, forward P/E of 19.44, PEG of 1.84. The spread between trailing and forward P/E is moderate, suggesting some earnings improvement is expected but not a dramatic re-rating. The PEG ratio sits in a range that most investors would consider fair — neither cheap nor obviously stretched relative to anticipated earnings. A current ratio reading of 1.96 points to holdings that are managing short-term obligations without apparent stress. Combining multiples and liquidity, the portfolio appears adequately priced for its current earnings trajectory, with balance sheet health providing a degree of downside resilience.
Margins & Cash Generation
Across the three margin layers, gross margin sits at 60.16%, operating margin at 29.21%, and free cash flow margin at 24.74%. The gross margin reading is exceptional — a reliable indicator of competitively advantaged businesses. Operating margins are in good shape, consistent with businesses that maintain reasonable earnings conversion after overhead. At this level, free cash flow margins suggest businesses that are building financial strength alongside revenue growth. Read together, these margins describe businesses that have earned their profitability rather than manufactured it through accounting — a meaningful quality signal.
Growth & Forward Outlook
On a forward-looking basis, TTM revenue growth of 18.57% a signal of steady demand without the volatility of high-growth names, while the estimated 12-month price change of 23.67%, where the target distribution indicates incremental upside rather than outsized repricing. Revenue growth and price targets are correlated but not the same — strong operations do not always translate to strong price appreciation, and vice versa. The forward return case rests on whether the businesses can sustain their operating trajectory long enough for analyst price targets to be reached or exceeded. The estimated 12-month price change is a weighted composite of analyst price target estimates adjusted by each holding's ETF weight, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.
Conclusion
Strong BuyThe full scorecard here is hard to argue with: capital efficiency is strong, margins are healthy, and growth is being priced constructively.
The views expressed above are derived from quantitative data only and should not be relied upon as financial advice. Investment decisions should be based on your own research and risk tolerance.